Last reviewed · How we verify
MEDI4736 + Tremelimumab
MEDI4736 (durvalumab) blocks PD-L1 to restore anti-tumor immunity, while tremelimumab blocks CTLA-4 to enhance T-cell activation, together providing dual checkpoint inhibition.
MEDI4736 (durvalumab) blocks PD-L1 to restore anti-tumor immunity, while tremelimumab blocks CTLA-4 to enhance T-cell activation, together providing dual checkpoint inhibition. Used for Unresectable or metastatic non-small cell lung cancer, Hepatocellular carcinoma, Mesothelioma.
At a glance
| Generic name | MEDI4736 + Tremelimumab |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Dual checkpoint inhibitor (PD-L1 inhibitor + CTLA-4 inhibitor) |
| Target | PD-L1 and CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MEDI4736 is a PD-L1 inhibitor that prevents tumor cells from suppressing immune responses by blocking the PD-L1/PD-1 interaction. Tremelimumab is a CTLA-4 antagonist that removes inhibitory signals on T cells, promoting their proliferation and activation. The combination leverages two complementary immune checkpoint pathways to maximize anti-tumor T-cell responses.
Approved indications
- Unresectable or metastatic non-small cell lung cancer
- Hepatocellular carcinoma
- Mesothelioma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
- Rash
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- IIT2025-03-YANG-LIFT-HCC (PHASE2)
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (PHASE1)
- TheraSphere With Durvalumab and Tremelimumab for HCC (PHASE2)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (PHASE2)
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (PHASE2)
- Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI4736 + Tremelimumab CI brief — competitive landscape report
- MEDI4736 + Tremelimumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI